23:38 , Oct 18, 2017 |  BC Innovations  |  Translation in Brief

Neutrophil bias

Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory phenotype in neutrophils that can treat stroke in mice. But safety issues around the recombinant cytokine have the team...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

PXL-01: Additional Phase II data

Additional data from a double-blind, European Phase II trial in 138 patients aged 15-65 undergoing flexor tendon repair surgery showed that 0.5 mL topical PXL-01 significantly improved joint flexibility at 6 months post-surgery vs. placebo...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Talactoferrin: Final Phase I/II data

Final data from a double-blind, U.S. Phase I/II trial in 120 pre-term infants showed that twice-daily 150 mg/kg talactoferrin missed the primary endpoint of reducing the incidence of nosocomial infections vs. placebo (10% vs. 15%,...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Talactoferrin: Phase III data

Data from 94 patients with NSCLC in the discontinued, double-blind, U.S. Phase III FORTIS-C trial showed that twice-daily 1.5 g oral talactoferrin in combination with carboplatin plus paclitaxel as first-line treatment led to an investigator-reported...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Ventria deal

Ventria acquired exclusive, royalty-free rights in the U.S., France and Canada to undisclosed patents related to recombinant human lactoferrin (rhLF) for an undisclosed one-time payment. The patents cover IP developed by Meristem Therapeutics,...
07:00 , Sep 24, 2012 |  BioCentury  |  Finance

Hopp stays the course

Despite experiencing mixed results over the past year, the Hopp family remains committed to placing big bets on innovative biotechnologies. In the latest example, the firm provided CureVac GmbH with €80 million to generate Phase...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

Agennix cancer news

Agennix unveiled details of a restructuring announced last month, including headcount cuts of 37 (55%) to 30. Cuts will come from U.S. and Germany sites, and remaining employees will work on activities related to Agennix's...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

Talactoferrin: Phase III data

The double-blind, international Phase III FORTIS-M trial in 742 stage IIIb/IV NSCLC patients who have failed >=2 prior therapies showed that twice-daily 1.5 g oral talactoferrin plus best supportive care (BSC) missed the primary endpoint...
00:31 , Aug 8, 2012 |  BC Extra  |  Clinical News

Agennix plummets on talactoferrin news

Agennix AG (Xetra:AGX) slid EUR 1.28 (69%) to EUR 0.57 on Tuesday after saying it will discontinue the Phase III FORTIS-C trial of oral talactoferrin as a first-line treatment for non-small cell lung cancer. The...
01:10 , Aug 7, 2012 |  BC Extra  |  Clinical News

Agennix's talactoferrin misses Phase III NSCLC endpoint

Agennix AG (Xetra:AGX) said twice-daily oral talactoferrin plus best supportive care missed the primary endpoint of median overall survival (OS) vs. placebo plus best supportive care in the Phase III FORTIS-M trial to treat refractory...